Tislelizumab
BGB-A317-A1217-202
Phase 2 mab completed
Quick answer
Tislelizumab for Cervical Cancer is a Phase 2 program (mab) at BeiGene with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeiGene
- Indication
- Cervical Cancer
- Phase
- Phase 2
- Modality
- mab
- Status
- completed